Journal of Kerman University of Medical Sciences

Immunohistochemical Expression of Estrogen Receptor in Pleomorphic Adenoma and Normal Salivary Gland Tissue

Document Type : Original Article

Authors

Fatemeh Asareh 1
Farzaneh Mehranfar 2

1 Department of Oral and Maxillofacial Pathology, School of Dentistry, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Periodontics, School of Dentistry, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

https://doi.org/10.34172/jkmu.2023.52
Abstract
Introduction: The expression of estrogen receptors in salivary gland tissue has been observed in some studies. Considering the histological similarity of salivary gland and breast tissue, as well as the prominent role of this receptor in the pathogenesis, treatment and prognosis of breast tumors, the aim of this study was to compare the immunohistochemical expression of estrogen receptor in pleomorphic adenoma (PA) and normal salivary gland tissue and assess its possible role in salivary gland tumors.
Materials and Methods: In this descriptive-analytical study, 26 samples of PA and 12 samples of normal salivary gland tissue were selected. Immunohistochemical staining was performed by standard invision method for estrogen receptor. The results were evaluated semi-quantitively as the percentage of nuclear and cytoplasmic stained cells separately by Mann- Whitney, Kruskal-Wallis and Fisher exact tests.
Results: All PA samples showed negative nuclear staining for estrogen receptor, but its expression was observed in the cytoplasm of ducts in 27% of tumors and in 59% of normal salivary gland tissue samples, but the difference was not statistically significant. In addition, no association was found between estrogen receptor expression and independent variables such as the type of stroma or the degree of cellularity in PA, age, sex and location of the specimen.
Conclusion: It seems that the expression of estrogen receptor does not play an effective role in the development and progression of PA tumor. However, its occurrence in the normal salivary gland ducts is considered and further studies in this field seem to be necessary.

Highlights

fatemeh asareh(google scholar)(pubmed)

farzaneh mehranfar(google scholar)(pubmed)

Keywords

Estrogen receptor
Pleomorphic adenoma
Salivary gland
Immunohistochemistry
Subjects
  1. Tarakji B, Nassani MZ, Sloan P. Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. Med Oral Patol Oral Cir Bucal. 2010;15(3):e432-6. doi: 4317/medoral.15.e432.
  2. Regezi JA, Sciubba J, Jordan RC. Oral Pathology. 5th ed. Missouri: Saunders; 2008. p. 195-6.
  3. Neville BW, Damm DD, Allen CM, Chi AC. Oral and Maxillofacial Pathology. 4th ed. Missouri: Elsevier; 2016. p. 444-6.
  4. Maitra A. The endocrine system. In: Kumar V, Abbas AK, Fausto N, Mitchell R, eds. Robbins Basic Pathology. 8th ed. Philadelphia, PA: Saunders; 2007. p. 752.
  5. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 2005;19(8):1951-9. doi: 10.1210/me.2004-0390.
  6. Tsinti M, Kassi E, Korkolopoulou P, Kapsogeorgou E, Moutsatsou P, Patsouris E, et al. Functional estrogen receptors alpha and beta are expressed in normal human salivary gland epithelium and apparently mediate immunomodulatory effects. Eur J Oral Sci. 2009;117(5):498-505. doi: 10.1111/j.1600-0722.2009.00659.x.
  7. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006;58(4):773-81. doi: 10.1124/pr.58.4.8.
  8. Yoshimura T, Sumida T, Liu S, Onishi A, Shintani S, Desprez PY, et al. Growth inhibition of human salivary gland tumor cells by introduction of progesterone (Pg) receptor and Pg treatment. Endocr Relat Cancer. 2007;14(4):1107-16. doi: 10.1677/erc.1.01253.
  9. Ito FA, Ito K, Coletta RD, Vargas PA, Lopes MA. Immunohistochemical study of androgen, estrogen and progesterone receptors in salivary gland tumors. Braz Oral Res. 2009;23(4):393-8. doi: 10.1590/s1806- 83242009000400008.
  10. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-72. doi: 10.5858/134.7.e48.
  11. Kumar V, Abbas AK, Fausto N, Mitchell R. Robbins Basic Pathology. 8th ed. Philadelphia, PA: Saunders; 2007. p. 20-1, 185,749.
  12. Ogushi T, Takahashi S, Takeuchi T, Urano T, Horie-Inoue K, Kumagai J, et al. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res. 2005;65(9):3700- 6. doi: 10.1158/0008-5472.can-04-3497.
  13. Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K. Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer. PLoS One. 2009;4(8):e6523. doi: 10.1371/journal.pone.0006523.
  14. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res. 2009;69(15):6100-6. doi: 10.1158/0008-5472.can-09-0506.
  15. Villa E, Colantoni A, Cammà C, Grottola A, Buttafoco P, Gelmini R, et al. Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol. 2003;21(3):441-6. doi: 10.1200/ jco.2003.11.051.
  16. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res. 2005;11(20):7280-7. doi: 10.1158/1078-0432. ccr-05-0498.
  17. Marotti JD, Collins LC, Hu R, Tamimi RM. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 2010;23(2):197-204. doi: 10.1038/ modpathol.2009.158.
  18. Wong MH, Dobbins TA, Tseung J, Tran N, Lee CS, O’Brien CJ, et al. Oestrogen receptor beta expression in pleomorphic adenomas of the parotid gland. J Clin Pathol. 2009;62(9):789- 93. doi: 10.1136/jcp.2009.065102.
  19. Barrera JE, Shroyer KR, Said S, Hoernig G, Melrose R, Freedman PD, et al. Estrogen and progesterone receptor and p53 gene expression in adenoid cystic cancer. Head Neck Pathol. 2008;2(1):13-8. doi: 10.1007/s12105-007-0032-3.
  20. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol. 2003;119(6):801-6. doi: 10.1309/rvtp-1g0q-727w-juqd.
  21. Teymoortash A, Lippert BM, Werner JA. Steroid hormone receptors in parotid gland cystadenolymphoma (Warthin’s tumour). Clin Otolaryngol Allied Sci. 2001;26(5):411-6. doi: 10.1046/j.1365-2273.2001.00494.x.
  22. de Souza AA, Altemani A, de Araujo NS, Texeira LN, de Araújo VC, Soares AB. Estrogen receptor, progesterone receptor, and HER-2 expression in recurrent pleomorphic adenoma. Clin Pathol. 2019;12:2632010x19873384. doi: 10.1177/2632010x19873384.
  23. Glas AS, Hollema H, Nap RE, Plukker JT. Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer. 2002;94(8):2211-6. doi: 10.1002/cncr.10445.
  24. Liang L, Williams MD, Bell D. Expression of PTEN, androgen receptor, HER2/neu, cytokeratin 5/6, estrogen receptor-beta, HMGA2, and PLAG1 in salivary duct carcinoma. Head Neck Pathol. 2019;13(4):529-34. doi: 10.1007/s12105-018-0984- 5.
Journal of Kerman University of Medical Sciences
Volume 30, Issue 6 - Serial Number 6
November and December 2023
Pages 304-308

Home

Editorial Board

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us